Navigation Links
Evotec AG: R&D Update on 16 October 2007 Live on the Internet
Date:10/9/2007

HAMBURG, Germany and OXFORD, England, October 9 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) is going to hold an R&D Update in London on Tuesday 16 October 2007 at 13.00 pm BST (14.00 pm CET, 08.00 am US time East Coast) which will be broadcast live on the internet.

Jorn Aldag, (President & Chief Executive Officer), Dr John Kemp, (Chief Research & Development Officer) and Dr Tim Tasker, (EVP Clinical Development) will provide an update on the status and development plans for Evotec's Clinical Programs and Discovery Projects. In addition, we are delighted to announce that Dr Michael G Kelly, (SVP Research & Development) at Renovis, will present the Renovis Pipeline Programs.

To join the audio webcast and to access the presentation slides you will find a link on our home page http://www.evotec.com shortly before the event.

For those who prefer to listen to the presentation via phone, please dial:

From Europe: +49(0)69-5007-1308 (Germany)

+44(0)20-7806-1956 (UK)

From the US: +1-718-354-1388

Pass Code: 2793143

The on-demand version of the webcast will be available on our website: http://www.evotec.com - Investors - Webcasts.

About Evotec AG

Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programmes and through research collaborations, the Company is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries.

In proprietary projects, Evotec specialises in finding new treatments for diseases of the Central Nervous System. Evotec has three programmes in clinical development: EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer's disease and/or pain, and EVT 302, a MAO-B inhibitor in development for smoking cessation.

On 19 September 2007, Evotec announced that it has entered into a definitive agreement under which Evotec will acquire Renovis, a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of pain and inflammatory diseases.

Contact:

Evotec AG

Anne Hennecke

SVP, Investor Relations & Corporate Communications

Phone: +49(0)40-56081-286

Fax: +49(0)40-56081-333

E-Mail: anne.hennecke@evotec.com


'/>"/>
SOURCE Evotec AG
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Merge unveils updated medical imaging software
2. Merge announces sofware updates, upcoming acquisition
3. Tech Digest: Merge eMed product updates; Renaissance Learning 3rd qtr results
4. Solinus updates MailFoundry anti-spam hardware, switching to Linux
5. Dane County mapping software updated, available to public
6. Wingra Technologies updates data migration software
7. Firstlogics mailing-address update system gains Postal Service certification
8. Lands End Debuts Updated Virtual Model
9. Internet-enabled niche markets take center stage
10. Emergence of Internet video is changing the regulatory landscape
11. Viewing the Internet as a free-for-all can be costly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... In a list published by the Boston ... 76 fastest-growing private companies; a small percentage of the state's 615,000+ small businesses. The ... percent change in revenue from 2012 to 2015. , As this award ...
(Date:5/3/2016)... - And Other Rising Companies - a ... Biologics  - Biosimilar Drug Producers - Your ... Who are the most important and promising ... potentials? Discover, in our updated survey, organisations, outlooks from ... forecasting. Visiongain,s new study analyses ...
(Date:5/2/2016)... ... May 02, 2016 , ... Meister Media Worldwide ... fresh look and added functionality give the agricultural world a taste of Meister ... shift in agriculture – from precision farming via satellites and Unmanned Aerial Vehicles ...
(Date:4/29/2016)... ... 2016 , ... Amendia, Inc., a leading designer, developer, manufacturer ... completion of a significant transaction and partnership that positions Amendia for accelerated growth ... Kohlberg & Company, L.L.C. (“Kohlberg”), a leading private equity firm specializing in middle ...
Breaking Biology Technology:
(Date:3/10/2016)... Pa. , March 10, 2016   Unisys Corporation ... Customs and Border Protection (CBP) is testing its biometric ... San Diego to help identify certain non-U.S. ... . The test, designed to help determine the efficiency ... environment, began in February and will run until May 2016. ...
(Date:3/9/2016)... , March 9, 2016 ... identified that more than 23,000 public service employees either ... been receiving their salary unlawfully.    --> ... government identified that more than 23,000 public service employees ... had been receiving their salary unlawfully.    --> ...
(Date:3/8/2016)... RALEIGH, N.C. , March 8, 2016 /PRNewswire/ ... biometric sensor technology, today announced it has secured ... led by GII Tech, a new venture fund ... LLC, with additional participation from existing investors TDF ... use the funds to continue its triple-digit growth ...
Breaking Biology News(10 mins):